According to Fintel, on September 15, 2023, Needham maintained coverage of Staar Surgical (NASDAQ:STAA) with a Buy recommendation.
Analyst Price Forecast Suggests 33.50% Upside
As of August 31, 2023, the average one-year price target for Staar Surgical is $57.23. The forecasts range from a low of $45.45 to a high of $69.30. The average price target represents an increase of 33.50% from its latest reported closing price of $42.87.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Staar Surgical is $362 million, an increase of 18.43%. The projected annual non-GAAP EPS is $1.05.
What is the Fund Sentiment?
There are 553 funds or institutions reporting positions in Staar Surgical. This is a decrease of 55 owners or 9.05% in the last quarter. Average portfolio weight of all funds dedicated to STAA is 0.27%, a decrease of 37.49%. Total shares owned by institutions increased in the last three months by 1.46% to 54,912K shares. The put/call ratio of STAA is 1.45, indicating a bearish outlook.
What are Other Shareholders Doing?
Broadwood Capital holds 8,783K shares representing 18.11% ownership of the company. No change in the last quarter.
Baillie Gifford holds 5,110K shares representing 10.54% ownership of the company. In its prior filing, the firm reported owning 5,124K shares, representing a decrease of 0.27%. The firm increased its portfolio allocation in STAA by 106.96% over the last quarter.
Anatole Investment Management holds 2,043K shares representing 4.21% ownership of the company. No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 1,504K shares representing 3.10% ownership of the company. In its prior filing, the firm reported owning 1,487K shares, representing an increase of 1.16%. The firm decreased its portfolio allocation in STAA by 23.26% over the last quarter.
IJH – iShares Core S&P Mid-Cap ETF holds 1,466K shares representing 3.02% ownership of the company. In its prior filing, the firm reported owning 1,487K shares, representing a decrease of 1.43%. The firm decreased its portfolio allocation in STAA by 22.37% over the last quarter.
Staar Surgical Background Information
(This description is provided by the company.)
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or ‘ICL’, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.